Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ANRO
ANRO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANRO News
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
Feb 26 2026
PRnewswire
Helus Pharma Achieves Breakthrough in Depression Treatment
Feb 26 2026
Newsfilter
Alto Neuroscience to Participate in Upcoming Investor Conferences
Feb 23 2026
Newsfilter
Alto Completes Patient Enrollment for ALTO-101 Clinical Trial
Feb 13 2026
Newsfilter
Healthcare Stocks Surge in After-Hours Trading
Jan 28 2026
NASDAQ.COM
Alto Neuroscience and Others Under Investigation for Shareholder Claims
Jan 20 2026
Globenewswire
Alto Neuroscience Secures Patent for ALTO-207, Enhancing Depression Treatment Potential
Jan 14 2026
Businesswire
Alto Neuroscience Secures Patent for ALTO-207, Protecting Key Treatment Method Until Mid-2040s
Jan 14 2026
Newsfilter
Alto Neuroscience Grants 150,000 Stock Options at $12.80 to New Employee
Dec 03 2025
Newsfilter
Johnson Fistel, PLLP Launches Investigation for Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
Dec 01 2025
Globenewswire
Major Stocks on the Rise Monday: Jazz Pharmaceuticals, Sigma Lithium, Zymeworks, and More
Nov 17 2025
Benzinga
Alto Neuroscience Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Nov 17 2025
Benzinga
BTIG Begins Coverage of Alto Neuroscience with a Buy Rating and $27 Price Target
Nov 17 2025
Yahoo Finance
Jefferies Keeps Buy Rating on Alto Neuroscience and Increases Price Target to $25
Nov 12 2025
Benzinga
Alto Neuroscience Announces Financial Results and Key Business Developments for Q3 2025
Nov 12 2025
Newsfilter
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days
Nov 11 2025
PRnewswire
Show More News
